MX2009011802A - Imidazoquinolinas con propiedades inmunomoduladoras. - Google Patents

Imidazoquinolinas con propiedades inmunomoduladoras.

Info

Publication number
MX2009011802A
MX2009011802A MX2009011802A MX2009011802A MX2009011802A MX 2009011802 A MX2009011802 A MX 2009011802A MX 2009011802 A MX2009011802 A MX 2009011802A MX 2009011802 A MX2009011802 A MX 2009011802A MX 2009011802 A MX2009011802 A MX 2009011802A
Authority
MX
Mexico
Prior art keywords
imidazoquinolines
immuno
modulating properties
modulating
properties
Prior art date
Application number
MX2009011802A
Other languages
English (en)
Inventor
Roger Victor Bonnert
Thomas Mcinally
Stephen Thom
Hiroki Wada
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009011802(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2009011802A publication Critical patent/MX2009011802A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos de la fórmula (I) en donde Ra, R1, R2, R3, X1, Y1, Z1, A, n y m son de acuerdo a lo definido en la especificación, y sales farmacéuticamente aceptables de los mismos, así como procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia.
MX2009011802A 2007-05-08 2008-05-06 Imidazoquinolinas con propiedades inmunomoduladoras. MX2009011802A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91658607P 2007-05-08 2007-05-08
US2495708P 2008-01-31 2008-01-31
PCT/GB2008/050328 WO2008135791A1 (en) 2007-05-08 2008-05-06 Imidazoquinolines with immuno-modulating properties

Publications (1)

Publication Number Publication Date
MX2009011802A true MX2009011802A (es) 2009-11-18

Family

ID=39596464

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011802A MX2009011802A (es) 2007-05-08 2008-05-06 Imidazoquinolinas con propiedades inmunomoduladoras.

Country Status (27)

Country Link
US (2) US8436178B2 (es)
EP (1) EP2155743B1 (es)
JP (1) JP5400763B2 (es)
KR (1) KR20100016289A (es)
CN (1) CN101687867B (es)
AR (1) AR066492A1 (es)
AU (1) AU2008247165B2 (es)
BR (1) BRPI0811125A2 (es)
CA (1) CA2686163A1 (es)
CL (1) CL2008001357A1 (es)
CO (1) CO6251247A2 (es)
CY (1) CY1113339T1 (es)
DK (1) DK2155743T3 (es)
EC (1) ECSP099750A (es)
ES (1) ES2393037T3 (es)
HR (1) HRP20120895T1 (es)
IL (1) IL201572A0 (es)
MX (1) MX2009011802A (es)
MY (1) MY150519A (es)
PE (1) PE20090276A1 (es)
PL (1) PL2155743T3 (es)
PT (1) PT2155743E (es)
RU (1) RU2475487C2 (es)
TW (1) TW200902529A (es)
UY (1) UY31069A1 (es)
WO (1) WO2008135791A1 (es)
ZA (1) ZA200907547B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012964B2 (en) 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
WO2008004948A1 (en) * 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
JP5329444B2 (ja) * 2007-03-19 2013-10-30 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
SI2132209T1 (sl) 2007-03-19 2014-05-30 Astrazeneca Ab Spojine 9-substituiranega-8-okso-adenina, kot modulatorji Toll-like receptorja (TLR7)
AR065784A1 (es) * 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2138497A4 (en) * 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
EP2155743B1 (en) * 2007-05-08 2012-08-29 AstraZeneca AB Imidazoquinolines with immuno-modulating properties
SI2170888T1 (sl) 2007-06-29 2015-10-30 Gilead Sciences, Inc. Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
JPWO2009091031A1 (ja) * 2008-01-17 2011-05-26 大日本住友製薬株式会社 アデニン化合物の製造方法
WO2009091032A1 (ja) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. アデニン化合物の製造方法
ES2546213T3 (es) * 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
UA105764C2 (uk) 2008-03-24 2014-06-25 4 Сц Аг Заміщені імідазохіноліни
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
ES2661850T3 (es) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
MX2012004706A (es) 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2011084725A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
WO2012080728A1 (en) 2010-12-16 2012-06-21 Astrazeneca Ab Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy
ES2627433T3 (es) 2010-12-17 2017-07-28 Sumitomo Dainippon Pharma Co., Ltd. Derivados de purina
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
BR112014004782A2 (pt) 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
WO2013131984A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of rabies virus immunogens
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
EP2850067B1 (en) 2012-05-18 2017-08-16 Sumitomo Dainippon Pharma Co., Ltd. Carboxylic acid compounds
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
EP3092255A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating egfr expressing tumors
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
US11230559B2 (en) * 2017-01-06 2022-01-25 Hoffmann-La Roche Inc. Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
JP7169968B2 (ja) 2017-03-29 2022-11-11 住友ファーマ株式会社 ワクチンアジュバント製剤
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
KR20200019226A (ko) 2017-06-23 2020-02-21 버디 바이오파마슈티칼즈, 인크. 약학 조성물
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2019048036A1 (en) * 2017-09-06 2019-03-14 Biontech Ag SUBSTITUTED IMIDAZOQUINOLINES
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
US12226480B2 (en) 2017-12-21 2025-02-18 Sumitomo Pharma Co., Ltd. Combination drug including TLR7 agonist
CN112839673A (zh) 2018-07-23 2021-05-25 日本国立感染症研究所所长代表之日本国 包含流感疫苗的组合物
MX2021010669A (es) * 2019-03-07 2021-09-28 BioNTech SE Proceso para la preparacion de una imidazoquinolina sustituida.
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2021110614A1 (en) * 2019-12-03 2021-06-10 F. Hoffmann-La Roche Ag HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
CA3184740A1 (en) * 2020-07-08 2022-01-13 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
EP4237012A1 (en) 2020-10-30 2023-09-06 Avacta Life Sciences Limited Fap-activated serum extended half-life therapeutic conjugates
WO2024138157A1 (en) * 2022-12-22 2024-06-27 Synovo Gmbh Novel imidazoquinolines with immunostimulatory effects
CN117800965A (zh) * 2023-12-28 2024-04-02 南方医科大学 2-氨基-咪唑并喹啉衍生化合物及其制备方法和用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404768L (sv) 1983-09-27 1985-03-28 Ceskoslovenska Akademie Ved 9-(aminoalkyl)-8-hydroxiadeniner och sett for deras framstellning
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL78643A0 (en) * 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
GB8918267D0 (en) * 1989-08-10 1990-04-25 British Aerospace Weapon systems
EP0872478B1 (en) * 1991-03-01 2002-12-18 Minnesota Mining And Manufacturing Company Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH08165292A (ja) 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US5994361A (en) 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
JPH10507171A (ja) * 1994-10-05 1998-07-14 カイロサイエンス・リミテッド Ｐｎｐインヒビターとしてのプリンおよびグアニン化合物
TW552261B (en) * 1996-07-03 2003-09-11 Japan Energy Corp Novel purine derivative
CA2311742C (en) * 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
JPH11180981A (ja) 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4160645B2 (ja) 1997-12-24 2008-10-01 大日本住友製薬株式会社 新規アデニン誘導体及びその医薬用途
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
WO2000012487A1 (en) 1998-08-27 2000-03-09 Sumitomo Pharmaceuticals Co., Ltd. Pyrimidine derivatives
JP2000159767A (ja) 1998-11-26 2000-06-13 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン誘導体の新規製造法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US20020040032A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for stimulation of synthesis of synaptophysin in the central nervous system
WO2002004449A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of conditions affected by activity of multidrug transporters
WO2002004448A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions
AU2002239277A1 (en) * 2000-11-20 2002-05-27 Cor Therapeutics, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
SI1341791T1 (en) 2000-12-08 2005-10-31 3M Innovative Properties Company Thioether substituted imidazoquinolines
JP4331944B2 (ja) * 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
DE60230340D1 (de) * 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
US20060252774A1 (en) * 2002-05-02 2006-11-09 Vatner Stephen F Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases
US7427629B2 (en) * 2002-08-15 2008-09-23 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
KR101111085B1 (ko) 2002-09-27 2012-04-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 아데닌 화합물 및 그 용도
JP2004137157A (ja) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
JP2007524615A (ja) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
ATE465742T1 (de) * 2003-09-05 2010-05-15 Anadys Pharmaceuticals Inc Tlr7-liganden zur behandlung von hepatitis c
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
US8012964B2 (en) 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
EP1728792A4 (en) * 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-OXOADENINVERBINDUNG
MX2007013780A (es) * 2005-05-04 2008-02-05 Pfizer Ltd Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
JPWO2006129784A1 (ja) 2005-06-03 2009-01-08 独立行政法人理化学研究所 インターフェロン−α制御剤
JP2009504803A (ja) * 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US20090118263A1 (en) * 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
EP1939198A4 (en) * 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE COMPOUND
WO2007034916A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
US20080269240A1 (en) * 2005-09-22 2008-10-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel Adenine Compound
US20090105212A1 (en) * 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2008004948A1 (en) * 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
PT2038290E (pt) * 2006-07-07 2013-12-10 Gilead Sciences Inc Moduladores de receptor do tipo toll 7
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
EP2125792B1 (en) * 2007-02-19 2010-12-01 GlaxoSmithKline LLC Purine derivatives as immunomodulators
SI2132209T1 (sl) * 2007-03-19 2014-05-30 Astrazeneca Ab Spojine 9-substituiranega-8-okso-adenina, kot modulatorji Toll-like receptorja (TLR7)
JP5329444B2 (ja) * 2007-03-19 2013-10-30 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
AR065784A1 (es) * 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2155743B1 (en) * 2007-05-08 2012-08-29 AstraZeneca AB Imidazoquinolines with immuno-modulating properties
SI2170888T1 (sl) * 2007-06-29 2015-10-30 Gilead Sciences, Inc. Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
JPWO2009091031A1 (ja) * 2008-01-17 2011-05-26 大日本住友製薬株式会社 アデニン化合物の製造方法
WO2009091032A1 (ja) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. アデニン化合物の製造方法
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)

Also Published As

Publication number Publication date
DK2155743T3 (da) 2012-11-05
MY150519A (en) 2014-01-30
CY1113339T1 (el) 2016-06-22
HK1138849A1 (en) 2010-09-03
RU2475487C2 (ru) 2013-02-20
WO2008135791A8 (en) 2009-03-26
PE20090276A1 (es) 2009-04-21
ZA200907547B (en) 2013-04-24
ECSP099750A (es) 2010-02-26
JP5400763B2 (ja) 2014-01-29
US20100280001A1 (en) 2010-11-04
CO6251247A2 (es) 2011-02-21
BRPI0811125A2 (pt) 2017-05-09
CA2686163A1 (en) 2008-11-13
EP2155743B1 (en) 2012-08-29
AU2008247165A1 (en) 2008-11-13
PT2155743E (pt) 2012-10-30
CN101687867B (zh) 2013-10-02
CN101687867A (zh) 2010-03-31
KR20100016289A (ko) 2010-02-12
US20130225555A1 (en) 2013-08-29
PL2155743T3 (pl) 2013-01-31
US8436178B2 (en) 2013-05-07
JP2010526129A (ja) 2010-07-29
AR066492A1 (es) 2009-08-26
IL201572A0 (en) 2010-05-31
UY31069A1 (es) 2009-01-05
EP2155743A1 (en) 2010-02-24
WO2008135791A1 (en) 2008-11-13
HRP20120895T1 (hr) 2012-11-30
ES2393037T3 (es) 2012-12-18
CL2008001357A1 (es) 2009-01-02
AU2008247165B2 (en) 2011-11-03
RU2009140465A (ru) 2011-06-20
TW200902529A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
WO2008135791A8 (en) Imidazoquinolines with immuno-modulating properties
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
SG170069A1 (en) Quinoline derivatives
GEP20125487B (en) Organic compounds and their use
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
TW200745084A (en) Novel compounds
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
TW200745067A (en) Novel compounds
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX2009013501A (es) Compuestos piperidinicos y sus usos.
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
MX340233B (es) Agonistas de receptores de neurotrofina y sus usos como medicamentos.
WO2008006795A3 (en) Indole compounds
IN2012DN03042A (es)
MY156552A (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
MX2011012639A (es) Sales de derivados de pirazolon azo sustituidos con biciclo, metodo de preparacion y uso de los mismos.
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
MX2012008328A (es) Derivados de pirazina.

Legal Events

Date Code Title Description
FG Grant or registration